EMEA/EUROPEAN COMMISSION PHARMACEUTICAL NEWS IN BRIEFS
June 1st, 2009
BY KEITH NUTHALL
THE EUROPEAN Medicines Agency (EMEA) has recommended its first marketing authorisation for an advanced therapy medicinal product - ChondroCelect, developed by Belgium's TiGenix NV. It is a cell-based medicine, used to repair defects in the cartilage of the femoral condyle.
Other EMEA news:
*It has launched a public consultation on a new transparency policy - comments required by September 25 - http://www.emea.europa.eu/pdfs/human/press/pr/37692309en.pdf
*The agency has also released guidance in EudraVigilance individual case safety report data ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.